Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Final Verdict on the Link Between Vasectomies and Prostate Cancer Risk

      July 27, 2017
      By Brielle Urciuoli
      Article

      For years, people believed that there was a link between vasectomies and prostate cancer.

      Bimal Bhindi, MD

      Bimal Bhindi, MD

      Bimal Bhindi, MD

      In the 1980s and 1990s, reports were published noting that there may be a connection between vasectomies and prostate cancer. A team of researchers from the Mayo Clinic in Rochester, Minnesota and the University of Toronto sought a clearer answer. In examining much of the available evidence, they determined that getting a vasectomy will not increase a man’s risk of developing prostate cancer.

      “With the aim of shedding some light onto a debate that is 3 decades old, we conducted a systematic review of the literature and performed a meta-analysis, with a particular attention to study quality, to determine if there is an association between vasectomy and prostate cancer,” the researchers wrote in the study.

      Results of more than 40 studies were considered — comprising of more than 12 million participants. After eliminating the studies that were at high risk for bias, the researchers found a weak or nonsignificant association between prostate cancer and vasectomies.

      The study examined risk of different types of prostate cancer — high-grade prostate cancer, advanced prostate cancer and fatal prostate cancer – and did not find an increased risk for any of them.

      “At most, there is a trivial, non-clinically significant association between vasectomy and prostate cancer risk, that is unlikely to be causal,” Bimal Bhindi, MD, fellow of Urologic Oncology at the Mayo Clinic said in an interview with Oncology Nursing News. “This weak observed association may be due to residual unmeasured confounding in the synthesized studies. Concerns about prostate cancer risk shouldn't prevent men from considering vasectomy as a viable long-term contraceptive option.”

      Previous reports suggested that the effects of a vasectomy, such as hormonal imbalances, immunologic effects and cell proliferation changes may play a role in a man’s susceptibility to prostate cancer, however, the authors wrote that the exact mechanisms still have not been proven or understood — even in animal models.

      Further, many of the studies in decades prior were observational studies, which are often susceptible to confounding and other limitations.

      “Vasectomies are often done by urologists and general practitioners,” Bhindi said. “If men go in to see a GP or urologist, they are more likely to get a PSA test. In turn, if they get screened, they are more likely to have a prostate cancer detected.”

      An observational study, therefore, is much more likely to show that more men who get vasectomies get prostate cancer. But does this does not prove that the vasectomy was the cause of the cancer.

      Only an estimated 8 to 12% of couples use vasectomy as their form of birth control, but the authors on the study urge men not to fear prostate cancer when making that decision.

      “This association is unlikely to be causal and should not preclude the use of vasectomy as a long-term contraceptive option,” the study says.

      While Bhindi said that he cannot be sure that the low incidence of vasectomy as a birth control method is due to the notion that it might cause cancer, he did note that it could have been a deterring factor for some men.

      “When considering male contraceptive options, hearing that vasectomy might cause cancer can be highly dissuading, and may cause men to overlook several of the benefits of vasectomy as an effective and cost-efficient long-term contraceptive option,” he said.

      While many studies often leave room for further research, Bhindi actually said that this report ends the debate, once and for all.

      “We feel our study synthesizes the literature in a way that hopefully can bring closure to the debate. In the setting of limited research resources, we in fact advised against further research on this topic, as discussed in our paper,” he said.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Man standing in front of Oncology Nursing News-branded backdrop
      Brenda Martone
      Arash Rezazadeh Kalebasty
      Leapman
      Laura Wood on the Integration of Avelumab, Erdafitinib, and Enfortumab Vedotin into Urothelial Cancer Care
      Related Content

      Blue image of kidneys with renal tubules highlighted in red

      Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC

      Tim Cortese
      February 15th 2025
      Article

      Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.


      Oncology Nursing News

      A Look Back at 2022 FDA Approvals in Oncology

      Oncology Nursing News
      January 2nd 2023
      Podcast

      In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.


      Graphic of care providers, patients, and families conversing near large computers and health charts

      Digital Health Tool Helps Patients With Prostate Cancer During Consultations

      Bridget Hoyt
      February 14th 2025
      Article

      MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.


      Key Advances in Cancer Survivorship Toxicity Management

      Key Advances in Cancer Survivorship Toxicity Management

      Lindsay Fischer
      July 15th 2022
      Podcast

      In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.


      Rendering of prostate cancer cells

      Clinical Practice Gaps Persist in Biomarker Testing for mCRPC Management

      Darlene Dobkowski, MA
      February 13th 2025
      Article

      With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is needed to address these gaps.


      Rendering of a bladder and prostate, surrounded by images of cancerous cells

      Talazoparib-Enzalutamide Combo Increases OS in mCRPC

      Jordyn Sava
      February 13th 2025
      Article

      Patients with HRR-deficient metastatic castration-resistant prostate cancer saw a 14-month boost in OS and a 38% lower risk of death with talazoparib plus enzalutamide.

      Related Content

      Blue image of kidneys with renal tubules highlighted in red

      Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC

      Tim Cortese
      February 15th 2025
      Article

      Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.


      Oncology Nursing News

      A Look Back at 2022 FDA Approvals in Oncology

      Oncology Nursing News
      January 2nd 2023
      Podcast

      In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.


      Graphic of care providers, patients, and families conversing near large computers and health charts

      Digital Health Tool Helps Patients With Prostate Cancer During Consultations

      Bridget Hoyt
      February 14th 2025
      Article

      MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.


      Key Advances in Cancer Survivorship Toxicity Management

      Key Advances in Cancer Survivorship Toxicity Management

      Lindsay Fischer
      July 15th 2022
      Podcast

      In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.


      Rendering of prostate cancer cells

      Clinical Practice Gaps Persist in Biomarker Testing for mCRPC Management

      Darlene Dobkowski, MA
      February 13th 2025
      Article

      With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is needed to address these gaps.


      Rendering of a bladder and prostate, surrounded by images of cancerous cells

      Talazoparib-Enzalutamide Combo Increases OS in mCRPC

      Jordyn Sava
      February 13th 2025
      Article

      Patients with HRR-deficient metastatic castration-resistant prostate cancer saw a 14-month boost in OS and a 38% lower risk of death with talazoparib plus enzalutamide.

      Latest Conference Coverage

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      AI Tool May Predict Response, Resistance in Advanced RCC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.